NR3C2 and metabolic dysfunction-associated steatohepatitis: Of note, studies assessing the effects of pharmacologic MR antagonism using spironolactone or eplerenone (27, 28) have shown that MR antagonism prevents liver steatosis in animal models of NASH, reinforcing the role of MR in modulating steatosis development.